Publications by authors named "Marco Bacosi"
Management of HCV infection and related liver disease with treatment currently available lead to a sustained virological response in 20% of patients using interferon (IFN)-alpha mono-therapy and approximately 40-45% in those on combination therapy with ribavirin.The aim of the present investigation was to compare the effect of consensus interferon alphacon-1 (C-IFN), and IFN-alpha 2b plus ribavirin, in patients relapsing after treatment with interferon alone. A total of 112 randomised patients with relapsing HCV infection (M/F=53/59), were treated for 24 weeks with: (A) IFN-alpha 2b starting with 5/6MU/day till negativity of HCV-RNA followed by 3MU every other day, plus ribavirin 15mg/kg/day (n=34); (B) C-IFN 9microg/day (n=40); (C) ursodeoxycholic acid (UDCA; sodium salt) 450mg/day (n=37).
View Article and Find Full Text PDFArticle Synopsis
- Study aimed to improve hepatitis C treatment in older patients using amantadine (AH) alongside interferon (IFN) due to IFN's side effects.
- Out of 165 patients over 65 who had not responded to previous IFN treatments, three groups were formed: Group A received only AH, Group B received IFN alone, and Group C received both AH and IFN.
- Results showed that Group C had the highest percentage of patients achieving normal ALT levels and negative HCV-RNA, suggesting that the combination treatment was more effective and reduced side effects from IFN.